menu
    • menu
    [{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Slate Path Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I","graph3":"Tvardi Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Slate Path Capital","highestDevelopmentStatusID":"6","companyTruncated":"Tvardi Therapeutics \/ Slate Path Capital"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TTI-101","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"TTI-101","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tvardi Therapeutics \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Tvardi Therapeutics \/ Cara Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for TTI-101

    Menu

    TTI-101

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement

                            Details : Tvardi will merge with Cara, combining resources and expertise in STAT3 inhibition, including its mid-stage lead program, TTI-101, for the treatment of idiopathic pulmonary fibrosis.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2024

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : CARA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TT...

                            Details : TTI-101, an orally delivered, small molecule, direct inhibitor of STAT3, is being developed alone or in combination with nintedanib in phase 2 trial in patients with idiopathic pulmonary fibrosis.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2023

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel ST...

                            Details : TTI-101, an orally delivered, small molecule, direct inhibitor of STAT3, is being developed in phase 3 trial in patients with locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 22, 2023

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer

                            Details : TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3, a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 23, 2023

                            Lead Product(s) : TTI-101,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

                            Details : TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3. STAT3 is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironme...

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2022

                            Lead Product(s) : TTI-101,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

                            Details : TTI-101 is an orally-delivered, small molecule, direct STAT3 inhibitor. STAT3 has emerged as a central node of fibrosis and has been found to accumulate in the fibrotic lungs of IPF patients.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

                            Details : TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3. STAT3 is a key regulatory protein which plays a critical role in the pathogenesis of HCC by initiating tumorigenesis as well as promoting an immunosuppressive tumor microenvironme...

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 21, 2022

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101,Palbociclib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to B...

                            Details : Studies demonstrated that combination of TTI-101 with palbociclib is synergistic in arresting tumor growth in murine models derived from metastatic breast cancer patients who had developed resistance to palbociclib.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 07, 2022

                            Lead Product(s) : TTI-101,Palbociclib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Slate Path Capital

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

                            Details : The company’s lead product, TTI-101, is currently being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 27, 2021

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Slate Path Capital

                            Deal Size : $74.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Tvardi Therapeutics

                            U.S.A arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tvardi’s TTI-101 Receives $5 Million in Grant Funding to Support Clinical Trials and Translational Research

                            Details : Funding to support clinical trials of TTI-101 in hepatocellular carcinoma and gastrointestinal cancer as well as funding from the PREVENT program to support translational work of TTI-101 in HCC prevention.

                            Product Name : TTI-101

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 24, 2020

                            Lead Product(s) : TTI-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : $5.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth